G-202 is a pro-drug, consisting of cytotoxic analog of thapsigargin and a peptide to activate it at the tumor site. It is administered by intravenous infusion daily for 3 consecutive days on a 28 day cycle in patients with advanced hepatocellular carcinoma after progression on Sorafenib therapy.
Onartuzumab is a monoclonal antibody directed against the hepatocyte growth factor receptor (c-Met). In this Phase I study Onartuzumab is administered intravenously as a single agent and in combination with Sorafenib in patients with advanced hepatocellular carcinoma. Study has 2 arms: one will enroll patients who have received one previous systemic therapy and the other will enroll systemic treatment naïve patients.